Get the Stockscreener App
3.56
0.84%
-0.03
After Hours:
3.56
Savara Inc stock is traded at $3.56, with a volume of 1.97M.
It is down -0.84% in the last 24 hours and up +37.98% over the past month.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
See More
Previous Close:
$3.59
Open:
$3.59
24h Volume:
1.97M
Relative Volume:
1.47
Market Cap:
$615.30M
Revenue:
-
Net Income/Loss:
$-54.70M
P/E Ratio:
-10.79
EPS:
-0.33
Net Cash Flow:
$-51.36M
1W Performance:
-4.30%
1M Performance:
+37.98%
6M Performance:
+36.92%
1Y Performance:
-16.04%
1-Day Range:
$3.49
$3.675
1-Week Range:
$3.49
$3.9625
52-Week Range:
$1.89
$4.70
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
3.56 | 661.97M | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Nov-13-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-24 | Initiated | JMP Securities | Mkt Outperform |
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
DOW Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Dow Inc. Class Action Lawsuit - GlobeNewswire Inc.
SVRA Bronstein, Gewirtz & Grossman LLC Announces that Savara Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - MarketScreener
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Savara Inc. (SVRA) Investors to Inquire About Securities Fraud Class Action - Business Wire
Savara Inc. (NASDAQ:SVRA) Receives $6.67 Consensus Price Target from Brokerages - MarketBeat
Savara Inc. Faces Legal Battle Over MOLBREEVI Controversy - TipRanks
Portnoy Law Firm Announces Class Action on Behalf of Savara, Inc. Investors - GlobeNewswire
SVRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Savara Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Savara (NASDAQ:SVRA) Given New $11.00 Price Target at Guggenheim - MarketBeat
Important Notice to Long-Term Shareholders of Applied - GlobeNewswire
Exome Asset Management LLC Has $2.32 Million Position in Savara Inc. $SVRA - MarketBeat
HC Wainwright Issues Optimistic Estimate for Savara Earnings - MarketBeat
Savara Inc. Securities Lawsuit Investigation - Claim Depot
SVRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Savara Increases Estimate of Autoimmune PAP Prevalence in U.S., Advances MOLBREEVI Toward FDA Resubmission - MSN
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Pomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers - FinancialContent
Savara (NASDAQ:SVRA) Price Target Raised to $8.00 at Oppenheimer - MarketBeat
SAVARA ALERT: Bragar Eagel & Squire, P.C. Announces that a - GlobeNewswire
Savara Inc. (SVRA) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - FinancialContent
Securities Fraud Investigation Into Savara Inc. (SVRA) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm - Business Wire
SVRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Savara Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara - Business Wire
SVRA ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Savara Inc. Investors - Business Wire
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Savara Inc. (SVRA) - Louisiana First News
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Guggenheim raises Savara stock price target to $11 on manufacturing updates - Investing.com
Investor Alert: Robbins LLP Informs Investors of the Savara Inc. Class Action Lawsuit - PR Newswire
Oppenheimer Adjusts Savara Price Target to $8 From $6, Maintains Outperform Rating - MarketScreener
S P Trends: Is Savara Inc. impacted by rising ratesTrade Performance Summary & High Accuracy Swing Trade Signals - 뉴스영
Technical Models Suggest Savara Inc. May Rebound SoonJuly 2025 Recap & Verified Momentum Watchlists - beatles.ru
Savara (NASDAQ:SVRA) Trading 4.8% Higher Following Analyst Upgrade - MarketBeat
Is Savara Inc. impacted by rising rates2025 Key Lessons & Weekly High Return Stock Forecasts - classian.co.kr
ADAR1 Capital Management LLC Has $3.77 Million Stock Position in Savara Inc. $SVRA - MarketBeat
Walleye Capital LLC Invests $574,000 in Savara Inc. $SVRA - MarketBeat
Trend analysis for Savara Inc. this weekShare Buyback & Daily Oversold Bounce Ideas - Newser
Nantahala Capital Management LLC Acquires 550,116 Shares of Savara Inc. $SVRA - MarketBeat
Savara Showcases Promising Phase 3 Trial Data for Molgramostim at ATS 2025 - MSN
What are the risks of holding Savara Inc.July 2025 News Drivers & AI Enhanced Trade Execution Alerts - خودرو بانک
Regression analysis insights on Savara Inc. performanceJuly 2025 Breakouts & Weekly Setup with High ROI Potential - Newser
Can Savara Inc. grow without external fundingWeekly Market Outlook & AI Forecasted Entry/Exit Points - خودرو بانک
Nuveen LLC Makes New Investment in Savara Inc. $SVRA - MarketBeat
Is Savara Inc. subject to activist investor interestMarket Movers & Real-Time Stock Entry Alerts - خودرو بانک
Will Savara Inc. stock go up soonMarket Volume Report & Expert Curated Trade Setups - Newser
What high frequency data says about Savara Inc.Weekly Trend Summary & Consistent Growth Equity Picks - Newser
Savara Inc. to Present at Upcoming Healthcare Investor Conferences - MSN
H.C. Wainwright raises Savara stock price target to $8 on larger patient pool By Investing.com - Investing.com South Africa
Savara Inc. stock chart pattern explainedIPO Watch & Reliable Entry Point Alerts - Newser
Published on: 2025-09-05 01:53:57 - Newser
H.C. Wainwright raises Savara stock price target to $8 on larger patient pool - Investing.com Canada
Price action breakdown for Savara Inc.July 2025 Decliners & Daily Stock Trend Reports - Newser
What candlestick patterns are forming on Savara Inc.2025 Key Lessons & Weekly Top Gainers Alerts - Newser
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):